CTOs on the Move

Synthes

www.synthes.com

 
Synthes is a leading global medical device company. Through its five product groups (Trauma, Spine, Cranio-Maxillofacial, Biomaterials and Power Tools) it develops, produces and markets instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.synthes.com
  • 1302 Wrights Ln E
    West Chester, PA USA 19380
  • Phone: 610.719.5000

Executives

Name Title Contact Details

Similar Companies

Totient

Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics.

Western Biomedical Enterprises

Western Biomedical Enterprises is a Placentia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nucleome Therapeutics

Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More

SutroVax

SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax`s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax`s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales. SutroVax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum PCV compared head-to-head to current vaccines using well accepted immunological endpoints. In addition to its lead PCV product candidate, the Company also has a promising early-stage pipeline addressing other important disease areas. SutroVax`s conjugate vaccines are developed utilizing the Company`s exclusive rights to Sutro Biopharma`s Xpress CF Platform, a cell-free protein synthesis technology. SutroVax closed its $85M Series C round in May of 2018 and is financed by a world-class syndicate of private equity, venture capital and corporate venture investors with over $170M in capital raised since 2015.

Visionary Products Inc

Visionary Products Inc is a Draper, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.